Ulrich Emil Schaible
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulrich Emil Schaible has a total of 258 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Dallenga
Leibniz Lung Center
7 shared publications Jacqueline Eich
Department Cellular Microbiology, Program Area Infection, Research Center Borstel, Leibniz Lung Center
5 shared publications- Stefan Niemann
Research Centre Borstel Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany.
5 shared publications - Claus Feldmann
Institute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Engesserstrasse 15, D-76131 Karlsruhe, Germany
4 shared publications - Dominik Schwudke
Division of Bioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
4 shared publications Kristine Hagens
Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, Priority Area Infections, Parkallee 1-40, 23845 Borstel (Germany)
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1962333
Deciphering the role of TRPML1-mediated calcium homeostasis in innate immune cell responses during Mycobacterium tuberculosis infection
Background: Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) is able to survive and replicate within host cells of the myeloid cell lineage, a critical step in the development of active TB, achieved through multiple immune evasion mechanisms. TRPML1 (Mucolipin 1), a non-selective Ca 2+ ion channel belonging to the TRP superfamily, is predominantly expressed in innate immune cells and is localized intracellularly along the endosomal–lysosomal continuum. TRPML1-mediated Ca 2+ signalling is vital for lysosomal biogenesis and trafficking processes essential for effective immune responses. The mechanisms regulating TRPML1 channel function in myeloid cells during mycobacterial infection remain poorly characterized. Methods: During in vitro infection, TRPML1 expression was modulated in a time-dependent manner by Mtb and M. bovis BCG in murine macrophages, as well as in human neutrophils (PMNs) and macrophages (MDMs). Using pharmacological modulation of TRPML1 channel activity, we observed alterations in intracellular Ca 2+ concentrations following Mtb infection. Results: Here, we describe distinct TRPML1 expression patterns in granulomas from TB patients who had completed treatment for active TB, suggesting a potential role for TRPML1 in pathogenesis. We further demonstrate that Mtb infection is associated with altered TRPML1 expression and intracellular Ca 2+ homeostasis, accompanied by changes in ROS production, necrotic cell death and enhanced mycobacterial survival within host cells. Treatment of PMN-MDM cocultures with a TRPML1 antagonist, but not an agonist, was associated with increased reactive oxygen species (ROS) levels and necrotic cell death. Discussion: Here, we show that Mtb-mediated disruption of TRPML1 function is associated with altered intracellular Ca 2+ homeostasis and may contribute to impaired phagosome maturation, a process previously linked to TRPML1-dependent endolysosomal function, thereby potentially favoring mycobacterial survival within host cells. These findings suggest that Mtb-induced alterations in TRPML1 associated cellular Ca²⁺ homeostasis may impair Ca²⁺-dependent ROS production and cell death, potentially affecting intracellular Mtb survival. Our findings support a role for TRPML1 in maintaining myeloid cell Ca²⁺ homeostasis and suggest that TRPML1 may contribute to the innate immune response to Mtb infection.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1962333
Open AccessDeciphering the role of TRPML1-mediated calcium homeostasis in innate immune cell responses during Mycobacterium tuberculosis infection
Background: Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) is able to survive and replicate within host cells of the myeloid cell lineage, a critical step in the development of active TB, achieved through multiple immune evasion mechanisms. TRPML1 (Mucolipin 1), a non-selective Ca 2+ ion channel belonging to the TRP superfamily, is predominantly expressed in innate immune cells and is localized intracellularly along the endosomal–lysosomal continuum. TRPML1-mediated Ca 2+ signalling is vital for lysosomal biogenesis and trafficking processes essential for effective immune responses. The mechanisms regulating TRPML1 channel function in myeloid cells during mycobacterial infection remain poorly characterized. Methods: During in vitro infection, TRPML1 expression was modulated in a time-dependent manner by Mtb and M. bovis BCG in murine macrophages, as well as in human neutrophils (PMNs) and macrophages (MDMs). Using pharmacological modulation of TRPML1 channel activity, we observed alterations in intracellular Ca 2+ concentrations following Mtb infection. Results: Here, we describe distinct TRPML1 expression patterns in granulomas from TB patients who had completed treatment for active TB, suggesting a potential role for TRPML1 in pathogenesis. We further demonstrate that Mtb infection is associated with altered TRPML1 expression and intracellular Ca 2+ homeostasis, accompanied by changes in ROS production, necrotic cell death and enhanced mycobacterial survival within host cells. Treatment of PMN-MDM cocultures with a TRPML1 antagonist, but not an agonist, was associated with increased reactive oxygen species (ROS) levels and necrotic cell death. Discussion: Here, we show that Mtb-mediated disruption of TRPML1 function is associated with altered intracellular Ca 2+ homeostasis and may contribute to impaired phagosome maturation, a process previously linked to TRPML1-dependent endolysosomal function, thereby potentially favoring mycobacterial survival within host cells. These findings suggest that Mtb-induced alterations in TRPML1 associated cellular Ca²⁺ homeostasis may impair Ca²⁺-dependent ROS production and cell death, potentially affecting intracellular Mtb survival. Our findings support a role for TRPML1 in maintaining myeloid cell Ca²⁺ homeostasis and suggest that TRPML1 may contribute to the innate immune response to Mtb infection.
- Open Access
- 25 December 2024
- Published by Springer Nature in Research Square
High Abundance of Gut Bacteroides in Early Childhood correlates with Microbiome Stability and Resilience after Antibiotic Treatment and with Increased Risk for Childhood Infections
Background Early childhood events, up to the age of two, are critical for the development of the microbiome and balanced immunity later in life. We investigated whether susceptibility to infections and microbiome resilience after antibiotic treatment are associated with key taxa in the early childhood microbiota. Therefore, we performed longitudinal microbiota analysis from stool samples of children within the German LöwenKIDS intensified subcohort. According to the exposure to antibiotic treatment, sample groups were defined as never-treated controls, 45–225 days pre-treatment (pre45-225), 0–30 days pre-treatment (pre0-30), 0–30 days post-treatment (post0-30), or > 90 days post-treatment and age > 540 days (post > 90). Results 1176 stool samples of 162 children were included in our analysis, of which 49 children received antibiotics. Using generalized linear mixed models adjusted for age, we show that high abundance of Bacteroides was associated with receiving antibiotic treatment later, while low Bacteroides abundance before treatment was associated with low alpha diversity and increased beta diversity post treatment. Conclusions Our data suggest a key role of the genus Bacteroides for the susceptibility to infections requiring antibiotic treatment and for microbiome stability and resilience in early childhood.
- 25 December 2024
- Published by Springer Nature in Research Square
Open AccessHigh Abundance of Gut Bacteroides in Early Childhood correlates with Microbiome Stability and Resilience after Antibiotic Treatment and with Increased Risk for Childhood Infections
Background Early childhood events, up to the age of two, are critical for the development of the microbiome and balanced immunity later in life. We investigated whether susceptibility to infections and microbiome resilience after antibiotic treatment are associated with key taxa in the early childhood microbiota. Therefore, we performed longitudinal microbiota analysis from stool samples of children within the German LöwenKIDS intensified subcohort. According to the exposure to antibiotic treatment, sample groups were defined as never-treated controls, 45–225 days pre-treatment (pre45-225), 0–30 days pre-treatment (pre0-30), 0–30 days post-treatment (post0-30), or > 90 days post-treatment and age > 540 days (post > 90). Results 1176 stool samples of 162 children were included in our analysis, of which 49 children received antibiotics. Using generalized linear mixed models adjusted for age, we show that high abundance of Bacteroides was associated with receiving antibiotic treatment later, while low Bacteroides abundance before treatment was associated with low alpha diversity and increased beta diversity post treatment. Conclusions Our data suggest a key role of the genus Bacteroides for the susceptibility to infections requiring antibiotic treatment and for microbiome stability and resilience in early childhood.
- Open Access
- 30 August 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (9) , ofae442
Association Between Vitamin D Insufficiency and Impaired Bone Density Among Adolescents With Perinatally Acquired HIV Infection
Stunting and pubertal delay are common among children growing up with human immunodeficiency virus (HIV) and are associated with bone and muscle impairments. We investigated factors associated with bone density and muscle function in adolescents living with HIV (ALWH). The VITALITY trial (PACTR202009897660297) investigated whether vitamin D and calcium supplementation improves musculoskeletal health among ALWH. A total of 842 ALWH aged 11–19 years, established on antiretroviral therapy (ART) for ≥6 months, were enrolled from HIV clinics in Zambia and Zimbabwe. Clinical history and examination were undertaken, and serum 25-hydroxyvitamin D3 (25[OH]D3) was measured. Dual-energy X-ray absorptiometry measured total-body-less-head bone mineral density adjusted for height (TBLH-BMDHT), and lumbar spine bone mineral apparent density (LS-BMAD) z scores. The association between a priori–defined covariates and musculoskeletal outcomes were investigated using baseline enrollment data and multivariable logistic regression. TBLH-BMDHT z scores were impaired (mean, −1.42 for male and −0.63 female participants), as were LS-BMAD z scores (mean −1.15 for male and −0.47 for female participants). In bivariate analysis, early pubertal stage, less physical activity, and older age at ART initiation were associated with lower TBLH-BMDHT z scores. Younger age, early pubertal stage, and low socioeconomic status were associated with lower LS-BMAD z scores. Grip-strength-for-height and jump-power-for-height z scores were associated with lower TBLH-BMDHT and LS-BMAD z scores. Low dietary vitamin D and calcium were associated with lower adjusted TBLH-BMDHT z scores. Lower 25(OH)D3 was associated with lower adjusted TBLH-BMDHT and LS-BMAD z scores. Deficits in bone density are common in ALWH. Vitamin D and calcium supplementation and promotion of exercise may improve musculoskeletal health among perinatally infected ALWH.
- 30 August 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (9) , ofae442
Open AccessAssociation Between Vitamin D Insufficiency and Impaired Bone Density Among Adolescents With Perinatally Acquired HIV Infection
Stunting and pubertal delay are common among children growing up with human immunodeficiency virus (HIV) and are associated with bone and muscle impairments. We investigated factors associated with bone density and muscle function in adolescents living with HIV (ALWH). The VITALITY trial (PACTR202009897660297) investigated whether vitamin D and calcium supplementation improves musculoskeletal health among ALWH. A total of 842 ALWH aged 11–19 years, established on antiretroviral therapy (ART) for ≥6 months, were enrolled from HIV clinics in Zambia and Zimbabwe. Clinical history and examination were undertaken, and serum 25-hydroxyvitamin D3 (25[OH]D3) was measured. Dual-energy X-ray absorptiometry measured total-body-less-head bone mineral density adjusted for height (TBLH-BMDHT), and lumbar spine bone mineral apparent density (LS-BMAD) z scores. The association between a priori–defined covariates and musculoskeletal outcomes were investigated using baseline enrollment data and multivariable logistic regression. TBLH-BMDHT z scores were impaired (mean, −1.42 for male and −0.63 female participants), as were LS-BMAD z scores (mean −1.15 for male and −0.47 for female participants). In bivariate analysis, early pubertal stage, less physical activity, and older age at ART initiation were associated with lower TBLH-BMDHT z scores. Younger age, early pubertal stage, and low socioeconomic status were associated with lower LS-BMAD z scores. Grip-strength-for-height and jump-power-for-height z scores were associated with lower TBLH-BMDHT and LS-BMAD z scores. Low dietary vitamin D and calcium were associated with lower adjusted TBLH-BMDHT z scores. Lower 25(OH)D3 was associated with lower adjusted TBLH-BMDHT and LS-BMAD z scores. Deficits in bone density are common in ALWH. Vitamin D and calcium supplementation and promotion of exercise may improve musculoskeletal health among perinatally infected ALWH.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A77.2-A77
PA-404 Neutrophil associated markers in sputum to predict postTB lung impairment
Background Tuberculosis (TB) is the #1 bacterial killer worldwide. Despite of successful antibiotic treatment, exacerbated patients did not regain sufficient lung capacity and develop postTB lung disease (PTLD). We hypothesized, that neutrophils play an important role in disease exacerbation and associated marker can be used for early detection of PTLD. Methods 25 confirmed MDR-TB Patients were recruited, sputum samples were taken over 6 months and analyzed for neutrophil associated proteins by ELISA. TB severity was assessed at baseline and month 6 using spirometry (lung function) and x-ray (lung pathology). Patients were categorized in mild and severe diseased by using Ralph score (threshold 40 pts) or spirometry (threshold FVCResults 16 patients (64%) had a stable severe impairment in lung function and no improvement after 6 month was observed. In contrast, x-ray pathology was improving in 10 patients (40%) and remained stable severe in 10 patients (40%). Ralph scores were significantly higher in patients with impaired lung function. Neutrophil associated marker significantly declined under antibiotic treatment. Patients with stable severe impairment have significantly increased MMP8 sputum concentrations at baseline (p = 0.017) and increased concentrations of Calprotectin (p = 0.008), MPO (p = 0.034), ELA2 (p =0.031) and NGAL (p = 0.01) at week 2. In addition, Calprotectin (p = 0.005), MMP8 (p = 0.011) and NGAL (p = 0.03) concentrations were increased in males at month 4, while no sex differences in x-ray pathology was observed. Conclusion Early postTB lung impairment was associated with neutrophil proteins in acute TB and elucidate the impact of neutrophils on disease progression and immune pathology. These proteins will be further analyzed as targets for Host Directed Therapies to reduce oxidative stress, tissue degradation, as well as immune modulators to prevent PTLD. Funding: Funded by German Center for Infection Research
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A77.2-A77
Open AccessPA-404 Neutrophil associated markers in sputum to predict postTB lung impairment
Background Tuberculosis (TB) is the #1 bacterial killer worldwide. Despite of successful antibiotic treatment, exacerbated patients did not regain sufficient lung capacity and develop postTB lung disease (PTLD). We hypothesized, that neutrophils play an important role in disease exacerbation and associated marker can be used for early detection of PTLD. Methods 25 confirmed MDR-TB Patients were recruited, sputum samples were taken over 6 months and analyzed for neutrophil associated proteins by ELISA. TB severity was assessed at baseline and month 6 using spirometry (lung function) and x-ray (lung pathology). Patients were categorized in mild and severe diseased by using Ralph score (threshold 40 pts) or spirometry (threshold FVCResults 16 patients (64%) had a stable severe impairment in lung function and no improvement after 6 month was observed. In contrast, x-ray pathology was improving in 10 patients (40%) and remained stable severe in 10 patients (40%). Ralph scores were significantly higher in patients with impaired lung function. Neutrophil associated marker significantly declined under antibiotic treatment. Patients with stable severe impairment have significantly increased MMP8 sputum concentrations at baseline (p = 0.017) and increased concentrations of Calprotectin (p = 0.008), MPO (p = 0.034), ELA2 (p =0.031) and NGAL (p = 0.01) at week 2. In addition, Calprotectin (p = 0.005), MMP8 (p = 0.011) and NGAL (p = 0.03) concentrations were increased in males at month 4, while no sex differences in x-ray pathology was observed. Conclusion Early postTB lung impairment was associated with neutrophil proteins in acute TB and elucidate the impact of neutrophils on disease progression and immune pathology. These proteins will be further analyzed as targets for Host Directed Therapies to reduce oxidative stress, tissue degradation, as well as immune modulators to prevent PTLD. Funding: Funded by German Center for Infection Research
- Open Access
- 9 May 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (10) , 9478-9486
Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis
Tuberculosis (TB) is one of the most prevalent infectious diseases. The global TB situation is further complicated by increasing patient numbers infected with Mycobacterium tuberculosis (M.tb.) strains resistant to either one or two of the first-line therapeutics, promoted by insufficient treatment length and/or drug levels due to adverse reactions and reduced patient compliance. An intriguing approach to improve anti-TB therapy relates to nanocarrier-based drug-delivery systems, which enhance local drug concentrations at infection sites without systemic toxicity. Recently developed anti-TB antibiotics, however, are lipophilic and difficult to transport in aqueous systems. Here, the very lipophilic TB-antibiotics bedaquiline (BDQ) and BTZ (1,3-benzothiazin-4-one 043) are prepared as high-dose, amorphous nanoparticles via a solvent-antisolvent technique. The nanoparticles exhibit mean diameters of 60 ± 13 nm (BDQ) and 62 ± 44 nm (BTZ) and have an extraordinarily high drug load with 69% BDQ and >99% BTZ of total nanoparticle mass plus a certain amount of surfactant (31% for BDQ, In vitro and in vivo studies employing M.tb.-infected macrophages and susceptible C3HeB/FeJ mice show promising activity, which outperforms conventional BDQ/BTZ solutions (in DMF or DMSO) with an up to 50% higher efficacy upon pulmonary delivery. In vitro, the BDQ/BTZ nanoparticles demonstrate their ability to cross the different biological barriers and to reach the site of the intracellular mycobacteria. In vivo, high amounts of the BDQ/BTZ nanoparticles are found in the lung and specifically inside granulomas, whereas only low BDQ/BTZ-nanoparticle levels are observed in spleen or liver. Thus, pulmonary delivered BDQ/BTZ nanoparticles are promising formulations to improve antituberculosis treatment.
- 9 May 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (10) , 9478-9486
Open AccessAmorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis
Tuberculosis (TB) is one of the most prevalent infectious diseases. The global TB situation is further complicated by increasing patient numbers infected with Mycobacterium tuberculosis (M.tb.) strains resistant to either one or two of the first-line therapeutics, promoted by insufficient treatment length and/or drug levels due to adverse reactions and reduced patient compliance. An intriguing approach to improve anti-TB therapy relates to nanocarrier-based drug-delivery systems, which enhance local drug concentrations at infection sites without systemic toxicity. Recently developed anti-TB antibiotics, however, are lipophilic and difficult to transport in aqueous systems. Here, the very lipophilic TB-antibiotics bedaquiline (BDQ) and BTZ (1,3-benzothiazin-4-one 043) are prepared as high-dose, amorphous nanoparticles via a solvent-antisolvent technique. The nanoparticles exhibit mean diameters of 60 ± 13 nm (BDQ) and 62 ± 44 nm (BTZ) and have an extraordinarily high drug load with 69% BDQ and >99% BTZ of total nanoparticle mass plus a certain amount of surfactant (31% for BDQ, In vitro and in vivo studies employing M.tb.-infected macrophages and susceptible C3HeB/FeJ mice show promising activity, which outperforms conventional BDQ/BTZ solutions (in DMF or DMSO) with an up to 50% higher efficacy upon pulmonary delivery. In vitro, the BDQ/BTZ nanoparticles demonstrate their ability to cross the different biological barriers and to reach the site of the intracellular mycobacteria. In vivo, high amounts of the BDQ/BTZ nanoparticles are found in the lung and specifically inside granulomas, whereas only low BDQ/BTZ-nanoparticle levels are observed in spleen or liver. Thus, pulmonary delivered BDQ/BTZ nanoparticles are promising formulations to improve antituberculosis treatment.
- Open Access
- 3 May 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (24) , 5460-5468
Amikacin@SiO 2 core@shell nanocarriers to treat pulmonal bacterial infections
AMC@SiO 2 core@shell nanocarriers (AMC: amikacin) with 200 nm AMC core, 20 nm silica shell, and unprecedented AMC load (80%) show high activity against Mycobacterium tuberculosis and Mycobacterium abscessus as pulmonal, often multiresistant bacteria.
- 3 May 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (24) , 5460-5468
Open AccessAmikacin@SiO 2 core@shell nanocarriers to treat pulmonal bacterial infections
AMC@SiO 2 core@shell nanocarriers (AMC: amikacin) with 200 nm AMC core, 20 nm silica shell, and unprecedented AMC load (80%) show high activity against Mycobacterium tuberculosis and Mycobacterium abscessus as pulmonal, often multiresistant bacteria.
- Open Access
- 26 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2584
Mycobacterium tuberculosis Acetyltransferase Suppresses Oxidative Stress by Inducing Peroxisome Formation in Macrophages
Mycobacterium tuberculosis (Mtb) inhibits host oxidative stress responses facilitating its survival in macrophages; however, the underlying molecular mechanisms are poorly understood. Here, we identified a Mtb acetyltransferase (Rv3034c) as a novel counter actor of macrophage oxidative stress responses by inducing peroxisome formation. An inducible Rv3034c deletion mutant of Mtb failed to induce peroxisome biogenesis, expression of the peroxisomal β-oxidation pathway intermediates (ACOX1, ACAA1, MFP2) in macrophages, resulting in reduced intracellular survival compared to the parental strain. This reduced virulence phenotype was rescued by repletion of Rv3034c. Peroxisome induction depended on the interaction between Rv3034c and the macrophage mannose receptor (MR). Interaction between Rv3034c and MR induced expression of the peroxisomal biogenesis proteins PEX5p, PEX13p, PEX14p, PEX11β, PEX19p, the peroxisomal membrane lipid transporter ABCD3, and catalase. Expression of PEX14p and ABCD3 was also enhanced in lungs from Mtb aerosol-infected mice. This is the first report that peroxisome-mediated control of ROS balance is essential for innate immune responses to Mtb but can be counteracted by the mycobacterial acetyltransferase Rv3034c. Thus, peroxisomes represent interesting targets for host-directed therapeutics to tuberculosis.
- 26 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2584
Open AccessMycobacterium tuberculosis Acetyltransferase Suppresses Oxidative Stress by Inducing Peroxisome Formation in Macrophages
Mycobacterium tuberculosis (Mtb) inhibits host oxidative stress responses facilitating its survival in macrophages; however, the underlying molecular mechanisms are poorly understood. Here, we identified a Mtb acetyltransferase (Rv3034c) as a novel counter actor of macrophage oxidative stress responses by inducing peroxisome formation. An inducible Rv3034c deletion mutant of Mtb failed to induce peroxisome biogenesis, expression of the peroxisomal β-oxidation pathway intermediates (ACOX1, ACAA1, MFP2) in macrophages, resulting in reduced intracellular survival compared to the parental strain. This reduced virulence phenotype was rescued by repletion of Rv3034c. Peroxisome induction depended on the interaction between Rv3034c and the macrophage mannose receptor (MR). Interaction between Rv3034c and MR induced expression of the peroxisomal biogenesis proteins PEX5p, PEX13p, PEX14p, PEX11β, PEX19p, the peroxisomal membrane lipid transporter ABCD3, and catalase. Expression of PEX14p and ABCD3 was also enhanced in lungs from Mtb aerosol-infected mice. This is the first report that peroxisome-mediated control of ROS balance is essential for innate immune responses to Mtb but can be counteracted by the mycobacterial acetyltransferase Rv3034c. Thus, peroxisomes represent interesting targets for host-directed therapeutics to tuberculosis.
- Open Access
- 25 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2554
Evaluation of Myeloperoxidase as Target for Host-Directed Therapy in Tuberculosis In Vivo
Due to the rise of tuberculosis cases infected with multi and extensively drug-resistant Mycobacterium tuberculosis strains and the emergence of isolates resistant to antibiotics newly in clinical use, host-directed therapies targeting pathogenesis-associated immune pathways adjunct to antibiotics may ameliorate disease and bacterial clearance. Active tuberculosis is characterized by neutrophil-mediated lung pathology and tissue destruction. Previously, we showed that preventing M. tuberculosis induced necrosis in human neutrophils by inhibition of myeloperoxidase (MPO) promoted default apoptosis and subsequent control of mycobacteria by macrophages taking up the mycobacteria-infected neutrophils. To translate our findings in an in vivo model, we tested the MPO inhibitor 4-aminobenzoic acid hydrazide (ABAH) in C3HeB/FeJ mice, which are highly susceptible to M. tuberculosis infection manifesting in neutrophil-associated necrotic granulomas. MPO inhibition alone or as co-treatment with isoniazid, a first-line antibiotic in tuberculosis treatment, did not result in reduced bacterial burden, improved pathology, or altered infiltrating immune cell compositions. MPO inhibition failed to prevent M. tuberculosis induced neutrophil necrosis in C3Heb/FeJ mice in vivo as well as in murine neutrophils in vitro. In contrast to human neutrophils, murine neutrophils do not respond to M. tuberculosis infection in an MPO-dependent manner. Thus, the murine C3HeB/FeJ model does not fully resemble the pathomechanisms in active human tuberculosis. Consequently, murine infection models of tuberculosis are not necessarily adequate to evaluate host-directed therapies targeting neutrophils in vivo.
- 25 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2554
Open AccessEvaluation of Myeloperoxidase as Target for Host-Directed Therapy in Tuberculosis In Vivo
Due to the rise of tuberculosis cases infected with multi and extensively drug-resistant Mycobacterium tuberculosis strains and the emergence of isolates resistant to antibiotics newly in clinical use, host-directed therapies targeting pathogenesis-associated immune pathways adjunct to antibiotics may ameliorate disease and bacterial clearance. Active tuberculosis is characterized by neutrophil-mediated lung pathology and tissue destruction. Previously, we showed that preventing M. tuberculosis induced necrosis in human neutrophils by inhibition of myeloperoxidase (MPO) promoted default apoptosis and subsequent control of mycobacteria by macrophages taking up the mycobacteria-infected neutrophils. To translate our findings in an in vivo model, we tested the MPO inhibitor 4-aminobenzoic acid hydrazide (ABAH) in C3HeB/FeJ mice, which are highly susceptible to M. tuberculosis infection manifesting in neutrophil-associated necrotic granulomas. MPO inhibition alone or as co-treatment with isoniazid, a first-line antibiotic in tuberculosis treatment, did not result in reduced bacterial burden, improved pathology, or altered infiltrating immune cell compositions. MPO inhibition failed to prevent M. tuberculosis induced neutrophil necrosis in C3Heb/FeJ mice in vivo as well as in murine neutrophils in vitro. In contrast to human neutrophils, murine neutrophils do not respond to M. tuberculosis infection in an MPO-dependent manner. Thus, the murine C3HeB/FeJ model does not fully resemble the pathomechanisms in active human tuberculosis. Consequently, murine infection models of tuberculosis are not necessarily adequate to evaluate host-directed therapies targeting neutrophils in vivo.
- Open Access
- 20 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 10137
Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies
Antimicrobial resistant (AMR) bacteria constitute a global health concern. Helicobacter pylori is a Gram-negative bacterium that infects about half of the human population and is a major cause of peptic ulcer disease and gastric cancer. Increasing resistance to triple and quadruple H. pylori eradication therapies poses great challenges and urges the development of novel, ideally narrow spectrum, antimicrobials targeting H. pylori. Here, we describe the antimicrobial spectrum of a family of nitrobenzoxadiazol-based antimicrobials initially discovered as inhibitors of flavodoxin: an essential H. pylori protein. Two groups of inhibitors are described. One group is formed by narrow-spectrum compounds, highly specific for H. pylori, but ineffective against enterohepatic Helicobacter species and other Gram-negative or Gram-positive bacteria. The second group includes extended-spectrum antimicrobials additionally targeting Gram-positive bacteria, the Gram-negative Campylobacter jejuni, and most Helicobacter species, but not affecting other Gram-negative pathogens. To identify the binding site of the inhibitors in the flavodoxin structure, several H. pylori-flavodoxin variants have been engineered and tested using isothermal titration calorimetry. An initial study of the inhibitors capacity to generate resistances and of their synergism with antimicrobials commonly used in H. pylori eradication therapies is described. The narrow-spectrum inhibitors, which are expected to affect the microbiota less dramatically than current antimicrobial drugs, offer an opportunity to develop new and specific H. pylori eradication combinations to deal with AMR in H. pylori. On the other hand, the extended-spectrum inhibitors constitute a new family of promising antimicrobials, with a potential use against AMR Gram-positive bacterial pathogens.
- 20 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 10137
Open AccessSelective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies
Antimicrobial resistant (AMR) bacteria constitute a global health concern. Helicobacter pylori is a Gram-negative bacterium that infects about half of the human population and is a major cause of peptic ulcer disease and gastric cancer. Increasing resistance to triple and quadruple H. pylori eradication therapies poses great challenges and urges the development of novel, ideally narrow spectrum, antimicrobials targeting H. pylori. Here, we describe the antimicrobial spectrum of a family of nitrobenzoxadiazol-based antimicrobials initially discovered as inhibitors of flavodoxin: an essential H. pylori protein. Two groups of inhibitors are described. One group is formed by narrow-spectrum compounds, highly specific for H. pylori, but ineffective against enterohepatic Helicobacter species and other Gram-negative or Gram-positive bacteria. The second group includes extended-spectrum antimicrobials additionally targeting Gram-positive bacteria, the Gram-negative Campylobacter jejuni, and most Helicobacter species, but not affecting other Gram-negative pathogens. To identify the binding site of the inhibitors in the flavodoxin structure, several H. pylori-flavodoxin variants have been engineered and tested using isothermal titration calorimetry. An initial study of the inhibitors capacity to generate resistances and of their synergism with antimicrobials commonly used in H. pylori eradication therapies is described. The narrow-spectrum inhibitors, which are expected to affect the microbiota less dramatically than current antimicrobial drugs, offer an opportunity to develop new and specific H. pylori eradication combinations to deal with AMR in H. pylori. On the other hand, the extended-spectrum inhibitors constitute a new family of promising antimicrobials, with a potential use against AMR Gram-positive bacterial pathogens.
- 16 August 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (16)
WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis
In view of emerging drug-resistant tuberculosis (TB), host-directed adjunct therapies are urgently needed to improve treatment outcomes with currently available anti-TB therapies. One approach is to interfere with the formation of lipid-laden “foamy” macrophages in the host, as they provide a nutrient-rich host cell environment for Mycobacterium tuberculosis (Mtb). Here, we provide evidence that Wnt family member 6 (WNT6), a ligand of the evolutionarily conserved Wingless/Integrase 1 (WNT) signaling pathway, promotes foam cell formation by regulating key lipid metabolic genes including acetyl-CoA carboxylase 2 (ACC2) during pulmonary TB. Using genetic and pharmacological approaches, we demonstrated that lack of functional WNT6 or ACC2 significantly reduced intracellular triacylglycerol (TAG) levels and Mtb survival in macrophages. Moreover, treatment of Mtb-infected mice with a combination of a pharmacological ACC2 inhibitor and the anti-TB drug isoniazid (INH) reduced lung TAG and cytokine levels, as well as lung weights, compared with treatment with INH alone. This combination also reduced Mtb bacterial numbers and the size of mononuclear cell infiltrates in livers of infected mice. In summary, our findings demonstrate that Mtb exploits WNT6/ACC2-induced storage of TAGs in macrophages to facilitate its intracellular survival, a finding that opens new perspectives for host-directed adjunctive treatment of pulmonary TB.
- 16 August 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (16)
WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis
In view of emerging drug-resistant tuberculosis (TB), host-directed adjunct therapies are urgently needed to improve treatment outcomes with currently available anti-TB therapies. One approach is to interfere with the formation of lipid-laden “foamy” macrophages in the host, as they provide a nutrient-rich host cell environment for Mycobacterium tuberculosis (Mtb). Here, we provide evidence that Wnt family member 6 (WNT6), a ligand of the evolutionarily conserved Wingless/Integrase 1 (WNT) signaling pathway, promotes foam cell formation by regulating key lipid metabolic genes including acetyl-CoA carboxylase 2 (ACC2) during pulmonary TB. Using genetic and pharmacological approaches, we demonstrated that lack of functional WNT6 or ACC2 significantly reduced intracellular triacylglycerol (TAG) levels and Mtb survival in macrophages. Moreover, treatment of Mtb-infected mice with a combination of a pharmacological ACC2 inhibitor and the anti-TB drug isoniazid (INH) reduced lung TAG and cytokine levels, as well as lung weights, compared with treatment with INH alone. This combination also reduced Mtb bacterial numbers and the size of mononuclear cell infiltrates in livers of infected mice. In summary, our findings demonstrate that Mtb exploits WNT6/ACC2-induced storage of TAGs in macrophages to facilitate its intracellular survival, a finding that opens new perspectives for host-directed adjunctive treatment of pulmonary TB.